Evidence map›Paper›PMID 41258366›Full record

ArticleScientific reports2025

Exploring biomarkers related to coagulation and immunity in myocardial infarction based on bioinformatics.

Jiwen Liu, Xuemei Chen, Xinmeichen Meng, Hui Huang, Jun Zhao, Zeyi Cheng, Lu Zhang, Junling Huang, Dongfeng Guo, Xiaoyan Yuan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiwen Liu *Department of Emergency Medicine, Shanghai Pudong New Area Gongli Hospital, Shanghai Pudong New area Miaopu Road 219, Shanghai, 200135, China.
Xuemei Chen *Postgraduate training base at Shanghai Gongli Hospital, Ningxia medical university, Shanghai, 200135, China.
Xinmeichen Meng *Postgraduate training base at Shanghai Gongli Hospital, Ningxia medical university, Shanghai, 200135, China.
Hui Huang *Department of Cardiology, Shanghai Pudong New Area Gongli Hospital, Shanghai, 200135, China.
Jun Zhao *Department of Cardiology, Shanghai Pudong New Area Gongli Hospital, Shanghai, 200135, China.
Zeyi Cheng *Department of Cardiovascular Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Lu ZhangInstitute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, 200433, China.
Junling HuangPostgraduate training base at Shanghai Gongli Hospital, Ningxia medical university, Shanghai, 200135, China.
Dongfeng GuoPostgraduate training base at Shanghai Gongli Hospital, Ningxia medical university, Shanghai, 200135, China.
Xiaoyan YuanDepartment of Emergency Medicine, Shanghai Pudong New Area Gongli Hospital, Shanghai Pudong New area Miaopu Road 219, Shanghai, 200135, China. yxy_828@126.com.

Funding

Commission(PWRd2022-04).Discipline Construction Project of Shanghai Pudong New Area Health Commission (Key Discipline Group) PWZxq2022-12Science and Technology Development Fund for Public Welfare Research Projects in Public Institutions of Shanghai Pudong New Area PKJ2024-Y28The Training Plan of discipline Leader of Shanghai Pudong new area Health Commission PWRd2022-04
6 · The paper itself

Abstract

Myocardial infarction (MI) remains a leading cause of global mortality, with the immune and coagulation systems playing pivotal roles in its pathophysiology. This study aimed to identify biomarkers associated with immune-related genes (IRGs) and coagulation-related genes (CRGs) in MI and to explore their potential regulatory mechanisms in treatment. Data from the GSE61144 and GSE60993 datasets were utilized. Four genes (IGF2R, TGFA, PLAUR, and MAPK14) were identified, exhibiting significantly elevated serum levels in patients with MI. Their distribution across tissues and single cells was further analyzed. Methylation site analysis of the N6-methyladenosine (m6A) biomarker revealed high-confidence methylation sites in IGF2R, PLAUR, and MAPK14. The RNA-binding protein (RBP) interactions were examined, revealing high-affinity binding sites for TARDBP in both IGF2R and MAPK14. GeneMANIA analysis highlighted biomarker-associated genes enriched in positive kinase regulation. Furthermore, a total of 20 potential drugs were predicted, with albuterol sulfate identified as a target for IGF2R, and molecular docking confirming the strongest binding affinity in the IGF2R-albuterol sulfate complex.

Indexed as

BiomarkersBlood CoagulationComputational BiologyMyocardial InfarctionHumansMolecular Docking SimulationReceptor, IGF Type 2BiomarkersReceptor, IGF Type 2

Identifiers

PMID41258366
PMCPMC12630877

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.